{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T02:03:00Z","timestamp":1722909780899},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T00:00:00Z","timestamp":1269993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> The ubiquitin\u2013proteasome system emerged as a new therapeutic target in cancer treatment. The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Human MM cell lines OPM\u20102, RPMI\u20108226, and U266 and primary MM cells from bone marrow aspirates were exposed to BSc2118. Cytotoxicity levels were evaluated using the MTT\u2010test. BSc2118\u2010induced apoptosis was analyzed by annexin\u2010V assay. Further methods used included proteasomal activity determination, cell cycle analysis, western blot, and transcription factor assays.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> In OPM\u20102, RPMI\u20108226, U266 cell lines and primary MM cells, BSc2118 caused dose\u2010dependent growth inhibitory effects. After 48\u2003h, dose\u2010dependent apoptosis occurred both in cell lines and primary myeloma cells irrespective of t(4;14). A significant G2\u2010M cell cycle arrest occurred after 24\u2003h. Furthermore, we observed a marked inhibition of intracellular proteasome activity, an increase in intracellular p21 levels, and an inhibition of NF\u2010\u03baB activation. The toxicity against PBMNC remained low, suggesting a broad therapeutic range of this agent.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Taken together, BSc2118 shows significant antimyeloma activity and may be considered as a promising agent in cancer drug development.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01450.x","type":"journal-article","created":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T07:47:07Z","timestamp":1270021627000},"page":"99-107","source":"Crossref","is-referenced-by-count":7,"title":["BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma"],"prefix":"10.1111","volume":"85","author":[{"given":"Jan","family":"Sterz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Kuckelkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Heider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren","family":"Mieth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Kleeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter\u2010M.","family":"Kloetzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Von Metzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2010.n.005"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.122"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0003"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.804"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.12.028"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.4008"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404413"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1547"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7725107"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/35056572"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041390107"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80753-9"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2007-0255"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2007.05.007"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404806"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1546"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.11.13.9367342"},{"key":"e_1_2_5_19_2","first-page":"2649","article-title":"In vivo ubiquitination and proteasome\u2010mediated degradation of p53","volume":"56","author":"Maki CG","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_5_20_2","first-page":"4620","article-title":"E7 protein of human papilloma virus\u201016 induces degradation of retinoblastoma protein through the ubiquitin\u2010proteasome pathway","volume":"56","author":"Boyer SN","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0454-6"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701370597"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.18.7071"},{"key":"e_1_2_5_25_2","first-page":"6677","article-title":"Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells","volume":"51","author":"Kanayama H","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050143"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016360"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2009.04.019"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00692.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-067710"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404843"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01164.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M502453200"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2614"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2007.10.021"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(88)90036-7"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161207780162908"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-1-51"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.6.879"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600822128"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.09.003"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01239.x"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00995.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01450.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01450.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T01:53:11Z","timestamp":1698630791000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01450.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,14]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01450.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01450.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,14]]}}}